Innovators in Cancer Immunology: Melanoma | Stories | PerkinElmer
Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Innovators in Cancer Immunology: Melanoma

May 12, 2017



Paul Tumeh, MD
Assistant Professor, Department of Medicine
Ronald Reagan UCLA Medical Center, Los Angeles
and UCLA Medical Center, Santa Monica, CA

To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.

Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.

Dr. Paul Tumeh, a rising star in the field of cancer immunology, who focuses on the identification of immune cell-types that mediate tumor rejections during PD-1 by identifying niches (i.e., discrete cellular microenvironments) within tumors that drive or inhibit response to PD1/PDL1 blocking therapies. He is using PerkinElmer’s Phenoptics platform to develop biomarkers that could potentially stratify patients to subcategories of those likely to respond, those likely to respond after the immune system is activated to engage with the tumor (‘primed’), and those not likely to respond even after ‘priming.’

Read More Stories Like This One

Tracking Elusive Breast Cancer Cells

New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the A...

Innovators in Cancer Immunology: Lymphoma

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses t...